Results 141 to 150 of about 841 (157)

Saroglitazar Reduces Predictor Lipid Biomarkers Of Cardiovascular Diseases

Atherosclerosis, 2019
M. Krishnappa, M. Shah, K. Parmar, S. Joshi, S. Maroo, D. Parmar   +5 more
openaire   +1 more source

Saroglitazar - A novel treatment for non-alcoholic steatohepatitis

AIP Conference Proceedings
Shifa Noorani, Manasa Ankam, C. H. S. V. Ganesh, Rahnuma Banu, P. Salome Satya Vani, Naveen Polarapu, Sarita Jangra, K. A. Shaima, Bhupinder Bhyan   +8 more
openaire   +1 more source

Saroglitazar

2017
openaire   +1 more source

Does Saroglitazar make a difference in MASLD management?

Journal of Clinical and Experimental Hepatology
Geeta Desai, Santosh Hajare
openaire   +1 more source

SAROGLITAZAR: A NEW CARDIOMETABOLIC TREATMENT FOR DIABETIC DYSLIPIDEMIA

International Journal of Research Publication and Reviews
Akanksha S. Lahoti, Smita J. kurkute, Asso.Prof. Sachin D. Wakchaure   +2 more
openaire   +1 more source

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

Case Medical Research, 2019
openaire   +1 more source

Pharmacokinetics and Safety Evaluation of Single‐Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment

Clinical Pharmacology in Drug Development, 2023
exaly  

Abstract #1311: Saroglitazar in Non-Alcoholic Fatty Liver Disease

Endocrine Practice, 2016
Shashank Joshi, Sound Ruby, Banshi Saboo, Rajeev Chawla, Sudhir Bhandari   +4 more
openaire   +1 more source

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

Liver International, 2018
Mukul Jain, Walter Wahli
exaly  

Virtual identification of novel PPARα/γ dual agonists by scaffold hopping of saroglitazar

Journal of Biomolecular Structure and Dynamics, 2018
Xian-Chao Cheng, Wen-Qing Jia, Wei-Ren Xu   +2 more
exaly